NASDAQ:NTLA News 8 October 2025

Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

What happened today Intellia Therapeutics (NASDAQ: NTLA) is under intense pressure after the company said the patient who experienced Grade 4 liver enzyme and bilirubin elevations in its Phase 3 MAGNITUDE study later died. In a Nov. 6 business update, CEO John Leonard said the treating physician cited “complicating comorbidities,” and Intellia is working with investigators and outside experts on a risk‑mitigation plan for nexiguran ziclumeran (nex‑z; NTLA‑2001), its in vivo CRISPR therapy for transthyretin amyloidosis (ATTR). The FDA’s clinical holds on MAGNITUDE (ATTR‑CM) and MAGNITUDE‑2 (ATTR‑PN) are still in effect pending a formal hold letter. GlobeNewswire+1 Sell‑side reaction was

7 November 2025

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Current News Stock Price and Market Activity CRSP is trading around the mid-$60s ahead of Monday’s open. By Reuters (Nov 2) it was ~$64.04 (up +4.86% on the day) reuters.com. (Nasdaq closes on Oct 31 showed ~$63.99 reuters.com.) Over the past month CRSP has gained roughly 17% genengnews.com, boosted by recent data releases. For example, a 3-day rally in mid-Oct lifted CRSP ~5% after the SyNTase/CTX460 results were announced genengnews.com. Technical indicators are mixed: the 14-day RSI is ~50 (neutral) and the MACD is slightly negative investing.com. Shorter moving averages (5/10/20-day around $63–$63.8) are giving buy signals investing.com, but the

2 November 2025

Biotechnology · CRISPR · Investing · NASDAQ:BEAM · NASDAQ:CRSP · NASDAQ:EDIT · NASDAQ:NTLA · NYSE:AZN · Premarket Analysis · Stock Market

Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?

NTLA Stock Plunges on Trial Halt Intellia’s stock implosion began early Monday after the biotech stunned investors with news of a trial pause. Before the market opened on Oct. 27, the Cambridge, MA-based company announced it had temporarily halted patient dosing and screening in two late-stage trials of its in vivo CRISPR therapy NTLA-2001 due to a serious adverse event ts2.tech. The immediate market reaction was brutal: NTLA stock plunged ~44% in pre-market trading and went on to close around $14.79 (down roughly 42% for the day) ts2.tech marketbeat.com. In dollar terms, shares that traded near $25–26 late last week collapsed into

28 October 2025

Biotechnology · CRISPR · Investment News · NASDAQ:NTLA · Pharma Industry · Stock Market

CRISPR Therapeutics Stock Soars on Gene-Editing Breakthroughs, Then Stumbles – What’s Next for CRSP?

Stock Price Rollercoaster in 2025 CRISPR Therapeutics’ stock has been on a wild ride this year. As of midday October 27, CRSP hovered around $67 per share – off its highs but still up dramatically from early 2025 levels genengnews.com. Over the past six months, the stock jumped 83% (from about $38 in April to the mid-$70s by mid-October) genengnews.com. Just this month, shares spiked 5% in three days after the company reported positive gene-editing data in a new therapy, briefly topping $71 genengnews.com. Year-to-date, CRSP had nearly doubled as of early October ts2.tech, reflecting growing investor enthusiasm for gene-editing

27 October 2025

Biotechnology · CRISPR · Gene Editing · Investment Analysis · NASDAQ:CRSP · NASDAQ:EDIT · NASDAQ:NTLA · Stock Market

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Background and Pipeline Intellia was an early pioneer of in-vivo CRISPR therapy. Based in Cambridge, MA, it was among the first to administer CRISPR-Cas9 therapies directly into patients ts2.tech. In 2021 Intellia reported the first clinical proof that in-body CRISPR editing could work – a single injection dramatically lowered the disease protein (transthyretin) in ATTR amyloidosis patients ts2.tech. Today, the company’s focus is on curative gene edits in severe diseases. Its lead programs are NTLA-2001 (nexiguran ziclumeran) for transthyretin amyloidosis (ATTR) and NTLA-2002 (lonvoguran ziclumeran) for hereditary angioedema (HAE) ts2.tech ts2.tech. Both use CRISPR delivered via lipid nanoparticles to

9 October 2025

Biotechnology · Gene Editing · Investment Analysis · NASDAQ:NTLA · Pharma News · Stock Market

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects

Quick Facts (as of 8 Oct 2025) Recent Performance and News Phase 1 data fuels rally Intellia’s October rally was triggered by longer‑term Phase 1 results for nexiguran ziclumeran (nex‑z), an in‑vivo CRISPR therapy for transthyretin (ATTR) amyloidosis. A GlobeNewswire release (Sept 25 2025) reported that a single dose produced a rapid, deep and durable reduction of serum TTR levels—mean reduction 92 % at 24 months and 90 % at 36 months globenewswire.com. Patients also showed clinical improvements or stabilization of neuropathy and cardiac markers globenewswire.com, and safety findings were mostly mild infusion‑related events globenewswire.com. CEO John Leonard said the data “demonstrate rapid, deep and durable TTR reductions with meaningful clinical

8 October 2025

Biotechnology · Company Analysis · Gene Editing · Investment Opportunities · NASDAQ:NTLA · Stocks

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia at a Glance: CRISPR Trailblazer in 2025 Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology company at the forefront of CRISPRgene editing medicines. Headquartered in Cambridge, MA, Intellia was one of the first companies to harness CRISPR-Cas9 technology to develop potential in vivo therapies – treatments delivered directly into the body to edit genes inside patients’ cells. In fact, Intellia reported the first-ever clinical evidence that CRISPR could provide a therapeutic benefit in humans via in-body gene editing, showing in 2021 that a one-time IV infusion could drastically lower a disease-causing protein in patients ts2.tech. This pioneering achievement, accomplished with their transthyretin amyloidosis (ATTR)